Net profit of Jubilant Ingrevia rose 79.93% to Rs 69.38 crore in the quarter ended December 2024 as against Rs 38.56 crore during the previous quarter ended December 2023. Sales rose 8.91% to Rs 1046.06 crore in the quarter ended December 2024 as against Rs 960.45 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1046.06960.45 9 OPM %13.229.95 - PBDT135.3489.32 52 PBT95.5855.08 74 NP69.3838.56 80 Powered by Capital Market - Live News

Jubilant Ingrevia announced that the Board of Directors of the Company at its meeting held on 28 January 2025, has recommended a Interim dividend of Rs.2.50 per share (i.e.250%), subject to the approval of the shareholders.Powered by Capital Market - Live News

Jubilant Ingrevia today announced the commissioning of its new cGMP compliant facility at Bharuch, Gujarat. The new facility will manufacture Nutraceuticals and Dietary-Active ingredients for human consumption. The facility is an extension of the company`s USFDA approved plant that is already supplying to the U.S., Europe, Japan and many other markets. It will be fully equipped to cater to the needs of the biggest marquee customers in the food, nutrition and cosmetics space. Customers seeking greener supply chains and high bio-content in their inputs, will especially stand to benefit. The Niacinamide from the new plant in addition to its various applications in skin and hair care, will also pave way for the Company to foray into infant nutrition market globally, with food grade Niacin. The production of these new grades of Vitamin B3 will significantly enhance the Company`s presence within value-added products with this high-value and high-margin offering. Powered by Capital Market - Live News

Jubilant Ingrevia will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live News

Jubilant Ingrevia has issued commercial paper of Rs 48 crore on 27 December 2024. Powered by Capital Market - Live News